Literature DB >> 25838343

Pathogenesis beyond the cancer clone(s) in multiple myeloma.

Giada Bianchi1, Nikhil C Munshi2.   

Abstract

Over the past 4 decades, basic research has provided crucial information regarding the cellular and molecular biology of cancer. In particular, the relevance of cancer microenvironment (including both cellular and noncellular elements) and the concept of clonal evolution and heterogeneity have emerged as important in cancer pathogenesis, immunologic escape, and resistance to therapy. Multiple myeloma (MM), a cancer of terminally differentiated plasma cells, is emblematic of the impact of cancer microenvironment and the role of clonal evolution. Although genetic and epigenetic aberrations occur in MM and evolve over time under the pressure of exogenous stimuli, they are also largely present in premalignant plasma cell dyscrasia such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM), suggesting that genetic mutations alone are necessary, but not sufficient, for myeloma transformation. The role of bone marrow microenvironment in mediating survival, proliferation, and resistance to therapy in myeloma is well established; and although an appealing speculation, its role in fostering the evolution of MGUS or SMM into MM is yet to be proven. In this review, we discuss MM pathogenesis with a particular emphasis on the role of bone marrow microenvironment.

Entities:  

Mesh:

Year:  2015        PMID: 25838343      PMCID: PMC4432002          DOI: 10.1182/blood-2014-11-568881

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  131 in total

Review 1.  Activation rules: the two-signal theories of immune activation.

Authors:  Alan G Baxter; Philip D Hodgkin
Journal:  Nat Rev Immunol       Date:  2002-06       Impact factor: 53.106

2.  The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications.

Authors:  T Hideshima; D Chauhan; R Schlossman; P Richardson; K C Anderson
Journal:  Oncogene       Date:  2001-07-27       Impact factor: 9.867

3.  SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells.

Authors:  D Chauhan; P Pandey; T Hideshima; S Treon; N Raje; F E Davies; Y Shima; Y T Tai; S Rosen; S Avraham; S Kharbanda; K C Anderson
Journal:  J Biol Chem       Date:  2000-09-08       Impact factor: 5.157

4.  Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk.

Authors:  Ya-Wei Qiang; Eugene Kopantzev; Stuart Rudikoff
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

5.  Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma.

Authors:  B Dankbar; T Padró; R Leo; B Feldmann; M Kropff; R M Mesters; H Serve; W E Berdel; J Kienast
Journal:  Blood       Date:  2000-04-15       Impact factor: 22.113

6.  Human myeloma cells promote the production of interleukin 6 by primary human osteoblasts.

Authors:  A Karadag; B O Oyajobi; J F Apperley; R G Russell; P I Croucher
Journal:  Br J Haematol       Date:  2000-02       Impact factor: 6.998

7.  Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells.

Authors:  R Catlett-Falcone; T H Landowski; M M Oshiro; J Turkson; A Levitzki; R Savino; G Ciliberto; L Moscinski; J L Fernández-Luna; G Nuñez; W S Dalton; R Jove
Journal:  Immunity       Date:  1999-01       Impact factor: 31.745

8.  Soluble syndecan-1 promotes growth of myeloma tumors in vivo.

Authors:  Yang Yang; Shmuel Yaccoby; Wei Liu; J Kevin Langford; Carla Y Pumphrey; Allison Theus; Joshua Epstein; Ralph D Sanderson
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

9.  Cytokines modulate telomerase activity in a human multiple myeloma cell line.

Authors:  Masaharu Akiyama; Teru Hideshima; Toshiaki Hayashi; Yu-Tzu Tai; Constantine S Mitsiades; Nicholas Mitsiades; Dharminder Chauhan; Paul Richardson; Nikhil C Munshi; Kenneth C Anderson
Journal:  Cancer Res       Date:  2002-07-01       Impact factor: 12.701

Review 10.  Marrow stromal stem cells.

Authors:  P Bianco; P Gehron Robey
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

View more
  100 in total

Review 1.  The bone-marrow niche in MDS and MGUS: implications for AML and MM.

Authors:  Irene M Ghobrial; Alexandre Detappe; Kenneth C Anderson; David P Steensma
Journal:  Nat Rev Clin Oncol       Date:  2018-01-09       Impact factor: 66.675

2.  Promising therapies in multiple myeloma.

Authors:  Giada Bianchi; Paul G Richardson; Kenneth C Anderson
Journal:  Blood       Date:  2015-06-01       Impact factor: 22.113

3.  ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment.

Authors:  Giada Bianchi; Peter G Czarnecki; Matthew Ho; Aldo M Roccaro; Antonio Sacco; Yawara Kawano; Annamaria Gullà; Anil Aktas Samur; Tianzeng Chen; Kenneth Wen; Yu-Tzu Tai; Maria Moscvin; Xinchen Wu; Gulden Camci-Unal; Matteo C Da Vià; Niccolo' Bolli; Tomasz Sewastianik; Ruben D Carrasco; Irene M Ghobrial; Kenneth C Anderson
Journal:  Cancer Discov       Date:  2021-04-10       Impact factor: 39.397

Review 4.  Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry.

Authors:  Kah Teong Soh; Joseph D Tario; Paul K Wallace
Journal:  Clin Lab Med       Date:  2017-12       Impact factor: 1.935

5.  Hypoxia promotes IL-32 expression in myeloma cells, and high expression is associated with poor survival and bone loss.

Authors:  Muhammad Zahoor; Marita Westhrin; Kristin Roseth Aass; Siv Helen Moen; Kristine Misund; Katarzyna Maria Psonka-Antonczyk; Mariaserena Giliberto; Glenn Buene; Anders Sundan; Anders Waage; Anne-Marit Sponaas; Therese Standal
Journal:  Blood Adv       Date:  2017-12-13

Review 6.  Evolutionary biology of high-risk multiple myeloma.

Authors:  Charlotte Pawlyn; Gareth J Morgan
Journal:  Nat Rev Cancer       Date:  2017-08-24       Impact factor: 60.716

7.  Quantitative and functional alterations of 6-sulfo LacNac dendritic cells in multiple myeloma.

Authors:  Baptiste Lamarthée; Frédéric de Vassoigne; Florent Malard; Nicolas Stocker; Inès Boussen; Clémence Médiavilla; Ruoping Tang; Fanny Fava; Laurent Garderet; Zora Marjanovic; Eolia Brissot; Mohamad Mohty; Béatrice Gaugler
Journal:  Oncoimmunology       Date:  2018-03-19       Impact factor: 8.110

8.  Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth.

Authors:  Renate Burger; Andreas Günther; Katja Klausz; Matthias Staudinger; Matthias Peipp; Eva Maria Murga Penas; Stefan Rose-John; John Wijdenes; Martin Gramatzki
Journal:  Haematologica       Date:  2016-09-22       Impact factor: 9.941

9.  TAZ functions as a tumor suppressor in multiple myeloma by downregulating MYC.

Authors:  Stacy Grieve; Gabriel Wajnberg; Miranda Lees; Simi Chacko; Jackson Weir; Nicolas Crapoulet; Tony Reiman
Journal:  Blood Adv       Date:  2019-11-26

Review 10.  Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies.

Authors:  Rebecca Karp Leaf; Hearn Jay Cho; David Avigan
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.